The study aims to evaluate the novel OptiCreatine formulation, which combines creatine with other bioactive compounds purported to enhance absorption and reduce gastrointestinal (GI) discomfort. Using a randomized, double-blind, crossover design, the study will compare the acute and chronic effects of OptiCreatine versus Creatine monohydrate in healthy, recreationally active adults. Participants will be asked to orally consume both the OptiCreatine and the creatine monohydrate. Primary outcomes include plasma creatine concentrations, gastrointestinal symptomatology, and fluid distribution measured through bioelectrical impedance spectroscopy.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Pharmacokinetic Outcomes: Concentration maximum (Cmax)
Timeframe: Over a period of 5 hrs. post dose of creatine
Pharmacokinetic Outcomes: Time to concentration maximum (Tmax)
Timeframe: Over a period of 5 hrs. post dose of creatine
Pharmacokinetic Outcomes: Area Under the Curve (AUC)
Timeframe: Over a period of 5 hrs. post dose of creatine